Targanta Therapeutics up 21% after seeking marketing approval for antibiotic
Targanta Therapeutics Corporation (Nasdaq:TARG) shares shot up more than 21% after the company announced Thursday it was seeking approval for marketing a broad-spectrum antibiotic in the European Union. The Cambridge, Mass.-based biopharmaceutical company said it is hoping to have the intravenous oritavancin treatment available in the EU by late 2009. The European Medicines Agency accepted the antibiotic, which the company said is effective in treating complex skin and soft tissue infections, for review after the medicine had undergone 19 clinical trials. Shares of Targanta were up 21.9% Thursday at $6.95 apiece.
For access to the full article, you must be a registered member - it's FREE.
Already a member? Please log in below
Not Registered?
Register today and enjoy all that SmallCapInvestor.com has to offer, including:
- Daily small cap stock profiles.
- Intra-day coverage of Russell 2000 companies.
- Research and insights from our analysts.
- Special reports.
